Clinical trial
Study of Atiprimod Treatment for Patients With Advanced Cancer
NCT00430014 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00430014 |
|---|---|
| Title | Study of Atiprimod Treatment for Patients With Advanced Cancer |
| Official title | An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Callisto Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Cancer |
| Intervention type | Drug |
| Interventions | Atiprimod |
| Enrollment | 28 |
| Start date | Mar 1, 2005 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Feb 1, 2007 |
| Last update posted | Feb 15, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: